Royalty Report: Drugs, Drug Discovery, Proteins – Collection: 263518

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Drug Discovery
  • Proteins
  • ribonucleic acid
  • Delivery
  • Genome
  • Antibody
  • Diagnostic
  • Biotechnology
  • Respiratory
  • Drug delivery
  • cardiac
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 263518

License Grant
Licensee receives from the Israeli Licensor a co-exclusive, sublicenseable license under the technology and collaboration technology to conduct collaborative development of development targets, compounds and products.

If Licensee exercises its option with respect to a development target and the parties enter into a license agreement, Licensee receives an exclusive, sublicenseable, license under our technology and collaboration technology to exploit compound and products with respect to such development target.

Licensee initially selected two development targets, including Glycogen Storage Disease III, and the parties agreed to a list of eight additional reserved targets related to rare diseases for which Licensee has the exclusive right to evaluate for collaborative development. During the reserved target exclusivity period Licensee may substitute a reserved target for a selected target, and/or exercise an expansion option by payment to us, whereby a reserved target will be deemed an additional target (and will preclude an additional reserved target in place of the converted reserved target). Further, during the reserved target exclusivity period, Licensee may replace a reserved target with a proposed new target, subject to certain conditions including whether we have the ability to partner such new target.

The Agreement additionally provides for limitations on our activities with third parties utilizing LUNAR lipid-mediated delivery technology with respect to a development target for a specified period of time. During the reserved target exclusivity period, we have agreed to exclusivity with respect to any product containing mRNA, including modified mRNA, or UNA oligomer with respect to such reserved target, and will first offer Licensee a right of first negotiation for any other RNA product or a product utilizing the LUNAR delivery technology with respect to such reserved target. The reserved target restrictions terminate upon expiration of the reserved target exclusivity period for each target, which may be extended on a reserved target-by-reserved target basis upon payment of an exclusivity extension fee.

On a reserved target-by-reserved target basis, following the target exclusivity period, Licensee receives an exclusive right of first negotiation to obtain an exclusive license to exploit RNA products with respect to such reserved target. Following the reserved target right of first negotiation period, if the parties have not entered into an agreement during a specified time period, the rights of Licensee terminate and we may grant a license or enter into a third-party arrangement with respect to such reserved target.

License Property
The collaboration technology specifically relates to the composition or formulation of a particular compound or product, or any method of using, making or administering a particular compound or product, and, all improvements to LUNAR lipid-mediated delivery technology and/or UNA oligomer chemistry.

The proprietary lipid nanopartical deliver system, LUNAR®, enables multiple nucleic acid medicines.  LUNAR® lipid-mediated delivery technology includes a diverse, growing library of over 150 proprietary lipids that Licensor rationally designed to be versatile, maximizing efficacy and increasing tolerability of a diverse selection of nucleic acids, target cell types and routes of administration. A key feature of our LUNAR lipids is their biodegradability, decreasing the undesired effects caused by lipid accumulation that are associated with tolerability issues present in other lipid-mediated RNA medicine delivery platforms.  LUNAR® and nucleic acid technologies are covered by a patent portfolio of 152 patents and patent applications, issued in the United States, China, Europe, Japan and other countries.

Unlocked Nucleic Acid (UNA) – are RNA analogues in which the C2’-C3’ bond of the ribose ring is absent. UNA chemistry technology can potentially be applied to multiple types of RNA medicines including mRNA, siRNA, microRNA and guide RNAs for gene editing. One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule.  UNAs can potentially improve the efficiency and specificity of siRNA-mediated protein suppression. siRNAs are short double-stranded RNA molecules. Once inside the cell, they become part of the RNA-induced silencing complex (RISC) and are split into two single siRNA strands. One of these strands stays with RISC and binds to any mRNA with a complementary sequence. If the wrong siRNA strand stays with RISC, it can bind to different mRNAs than the target mRNA and therefore inhibit translation of other proteins. This is an undesired off-target effect and is one of the major barriers to developing effective siRNA medicines. Incorporating a single UNA into siRNA molecules can make one of the strands preferentially bind to RISC improving specificity. Additionally, incorporation of UNA modifications can reduce susceptibility of the siRNA to nuclease degradation, improving the efficiency of siRNA-mediated protein suppression.  The comprehensive suite of UNA technology patents for therapeutic and reagent use, enabling Licensor to operate freely and to independently pursue nucleic acid therapeutic candidates incorporating this technology.

The Agreement provides that each party owns their respective collaboration know-how and collaboration patents and jointly own all joint collaboration know-how and joint collaboration patents.

Field of Use
This partnering is to develop up to ten mRNA therapeutic candidates for certain rare disease targets.  Target means any single protein (i.e., a protein designated by a unique NCBI reference sequence but including all of its naturally-occurring mutations and variants) that could be used as a potential treatment for a rare or ultra rare disease and that is expressed in the liver, including  Glycogen Storage Disease Type 3 (GSD), caused by genetic mutations in the glycogen debranching enzyme, known as  AGL, which leads to glycogen accumulation in liver and muscle.  There are approximately 10,000 patients worldwide with this type of GSD, who experience enlarged liver, increased fats in the blood, low blood sugar, decreased stature and late-onset muscle weakness.

The Licensed Field is for the diagnosis, prevention or treatment of human diseases.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 289255

License Grant
For the LNP Technology, Canadian Licensor will grant to Licensee a non-exclusive right to use the Licensor Combined Licensed Technology and the Category 1 Patents for use in developing and commercializing Supplemental Field Products. The license granted to Licensee supersedes and replaces the licenses granted to Licensee by Party A and Licensor in the current Supplemental Agreement. Licensee’s right to sub-license will be on a Sublicensable Product-by-Sublicensable Product basis.
License Property
LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 289256

License Grant
Licensor will grant to Canadian Licensee a non-exclusive license to any Licensor Intellectual Property for use in RNAi Products.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 370550

License Grant
Licensor licensed a worldwide exclusive right (on a target by target basis), under Licensor’s patent portfolio (122 patents and patent applications) and proprietary information and know-how relating to its modified SELEX processes and modified aptamers technology to make, use, sell, and have made, and have sold (a) commercial products produced by or incorporating Licensor licensed technologies and (b) commercial products intended for use in nucleic acid amplification that are rationally designed nucleic acid sequences that is a temperature dependent inhibitor of a licensed target. Licensor retained a non-exclusive right to make, use and have made the aptamers for internal research and development, including the right to grant non-exclusive licenses to Licensor collaborator for research and development purposes. The Amendment granted such company enforcement of licensed patent rights against third-party infringers to exclude in vivo imaging applications in the licensed field and licensed product.
License Property
SELEX (Systematic Evolution of Ligands by Exponential enrichment), a process typically short (e.g., approximately 20-50`mer) synthetic ssDNA sequences developed to bind specific protein targets. The power of the SELEX process comes from the intrinsic propensity of ssDNA to fold into unique three-dimensional shapes in solution. This means a large collection of ssDNA molecules represents a large collection of shapes, which include protein-like functional groups added to the 5-position of deoxyuridine residues of each reagent, bind to proteins with significantly higher affinity and specificity as compared to conventional unmodified aptamers, and identify functionally-active proteins in their native state rather than linearized epitopes (as many antibody based approaches do), or possible fragments of protein (as mass spectrometry, protein fingerprinting and “sequencing” technologies do).

Aptamers which are short, synthetic single stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Field of Use
Field of Use is for research and development of drugs relating to proteins and antibodies.

IPSCIO Record ID: 316393

License Grant
Licensor hereby grants to Licensee a non-exclusive royalty bearing license, under Licensor Contributed Know-How Patent Rights and Licensor Contributed Know-How, to use Licensee Accessible Program Clones and Proteins encoded therein in order to discover, research, develop, make, import, use, offer to sell include the right to grant sublicenses.
License Property
Program Clone means a clone (including the DNA sequence information, whether partial or full-length, pertaining to the clone), identified in the course of the Licensee Discovery Program or included in the Existing Tango Technology, Licensee Contributed Know-How or Licensor Contributed Know-How.

Licensee Program Methodology Patent Right means a Patent Right that relates to methods that are or were at any time included in Licensee Program Metholodogy.

Protein means a high molecular weight (i.e., weighing greater than 1000 daltons) polymer compound composed of a variety of amino acids joined by peptide linkages, including allelic variants thereof and post-translationally modified variants thereof (i.e., glycosylated Proteins). For purposes of this Agreement, Protein does not include an Antibody.

Small Molecule Drug means a therapeutic or prophylactic product, the active ingredient of which is a synthetic small molecule (including but not limited to a Peptido Mimetic), a natural product or a macromolecule that (a) is identified in a screening assay on the basis of its interaction with a biological target that has been identified through use of a Program Clone, or (b) is designed or developed using medicinal chemistry, SAR or combinatorial chemistry techniques to interact with a biological target that has been identified through use of a Program Clone, provided, however, that a Small Molecule Drug does not include any Therapeutic Product or any therapeutic and/or prophylactic product in which the active ingredient is a Protein, an Antibody, an Antisense Drug or a Gene Therapy Drug.

Gene Therapy Drug means any drug or drug candidate, excluding an Antisense Drug, which consists of nucleic acid or a functional analog, derivative or homologue thereof and which, upon delivery by any means, provides a gene product encoded therein which is expressed.

Antisense Drug means any drug or drug candidate which consists of nucleic acid or a functional analog, derivative or homologue thereof and which is complementary to a segment of DNA of a target gene or such target genes cognate RNA and which, upon delivery by any means, alters the transcription, processing, elaboration, RNA expression or Protein production of or by such target gene.

Antibody means (a) a molecule comprising four (4) polypeptide chains (two (2) identical light chains and two (2) identical heavy chains) that are held together by disulfide bonds and form two (2) identical antigen binding sites or (b) any combination, fragment or altered form of a molecule(s) of the type described in (a) (e.g., single chain antibodies).

Licensor Small Molecule Drug means a Small Molecule Drug identified or designed by Licensor through the use of a Licensor Accessible Program Clone and/or the Protein encoded therein.

Existing Tango Technology means the cDNA libraries, genomic sub-libraries, signal peptide trap libraries (including the clones derived from such libraries and the Proteins encoded therein) and the Proteins and all associated data and information.

Therapeutic Product means a therapeutic and/or prophylactic product in which the active ingredient is a Program Protein or a Derivative thereof.

Peptido Mimetic means  synthetic organic molecule that (a) is designed or developed using medicinal, SAR or combinatorial chemistry techniques to incorporate key structural features of a Protein (the 'Mimicked Protein'). Cb) if a peptide • has an amino acid sequence that is at least fifty percent (50%) different from that of the  Mimicked Protein, and (c) has a molecular weight that is less than twenty (20%) percent of that of the Mimicked Proteina,

Diagnostic Product means any diagnostic product, in the form of a device, compound, kit or service, with utility in the diagnosis, prognosis, prediction or disease management of a disorder that (a) is developed through the use of Licensee Program Know-How or, subject to any limitations on the use of such Know-How by Licensor, Licensee Contributed Know-How and/or is covered by a Valid Claim included in Licensee Program Know-How Patent Rights or, subject to any limitations on the use of such Patent Rights by Licensor, Licensee Contributed Know-How Patent Rights, (b) embodies, or operates through the detection of a Program Clone or a Program Protein (or a Derivative thereof), and (c) will complement the use of any therapeutic product under development or marketed by Licensor or a development or marketing partner of LIcensor (a Licensor Corresponding Drug).

Licensor Contributed Know-How means Know-How (a) which is necessary or useful in order to discover, develop, make, use, sell or seek approval to market Therapeutic Products, and (b) to which Licensor has the right to grant licenses or sublicenses without violating the terms of any agreement with a third party, and (c) which is in Licensors possession on the Effective Date or is developed or acquired by Licensor during the term, but not in the course, of the Licensee Discovery Program, and (d) which Licensor has elected to contribute to the Licensee Discovery Program through written notification to, and with the approval of, the Joint Management Team, which notification shall include any limitations on the use of such Know-How by Licensee, provided, however, that if such Know-How is a biological source for the identification of Program Clones, then the only permitted limitation shall be that Licensee shall not have the right to use any such Program Clone for the identification or design of Licensee Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified, and (e) which is not properly in the public domain.

Licensor Contributed Know-How Patent Right means a Patent Right that relates to Know-How that is or was at any time Licensor Contributed Know-How.

Licensor Selected Protein means a Program Protein selected by Licensor for further pre-clinical development, clinical development, manufacture and commercialization.

Licensor Accessible Program Clone means (a) a Program Clone that is not identified through the use of Licensee Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensee Contributed Know-How and with respect to which either (i) Licensee has not placed any limitation on Licensors use of such Program Clone for the identification or design of Licensor Small Molecule Drugs or (ii) Licensee has placed the limitation that Licensor shall not have the right to use such Program Clone for the identification or design of Licensor Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Licensee Discovery Program means the therapeutic Protein  discovery program to be undertaken by Licensee pursuant to this Agreement, with the goal of identifying and qualifying potential therapeutic Proteins for further pre-clinical development, clinical development, manufacturing and commercialization, as described in greater detail in the Program Plan.

Licensee Program Methodology means any methods (including without limitation bioinformatics tools, processes, protocols, assays, automated and semi-automated techniques, molecular biology methods and other methods for
the discovery, production and/or characterization of Proteins), that (a) are developed in the course of the Licensee Discovery Program, including any improvements in methods technology derived from, or based upon, any Licensor Contributed Know-How and/or Licensee Contributed Know-How and (b) are not properly in the public domain.

Licensee Accessible Program Clone means (a) a Program Clone  that is not identified through the use of Licensor Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensor Contributed Know-How and with respect to which either (i) Licensor has not placed any limitation on Licensees use of such Program Clone for the identification or design of Licensee Small  Molecule Drugs or (ii) Licensor has placed the limitation that Licensee shall not have the right to use such Program Clone for the identification or design of Licensee Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Field of Use
The field of use is for the therapeutic and/or prophylactic application in human health care of Proteins or Derivatives thereof. The goal is to identify and qualify potential therapeutic proteins, small molecule targets and diagnostics for further development and commercialization.

Licensee is in the business of employing various discovery methodologies to identify proteins with therapeutic utility.

IPSCIO Record ID: 289212

License Grant
Licensor grants a perpetual, non-exclusive, worldwide license, with the right to sub- license, under the `277 patent, the `582 patent, and any patents issuing from International Application No. PCT/US96/19698, any and all continuing applications, divisional applications, continuation-in-part applications, reissues, extensions, renewals and reexaminations thereof, and any U.S. and foreign counterparts thereof. In addition, Licensor agrees not to file any future patent infringement actions against Licensee for Licensees use of ThermoFluor Screening Technology that is consistent with the terms of this Agreement.
License Property
Licensor is a biopharmaceutical company dedicated to the development of a novel class of small molecule drugs that regulate gene expression. The Licensors lead therapeutic candidate is a novel anti-HIV compound that acts by inhibiting a viral protein/RNA interaction that is critical for the expression of viral structural proteins and essential for virus production.

Licensor is the owner of U.S. Patent 5,585,277, and U.S. Patent No. 5,679,582.

Atlas Technology shall mean the methods and processes generally disclosed in the specifications and claims of the `277 patent, the `582 patent and/or International Application No. PCT/US96/19698.

ThermoFluor Screening Technology shall mean the methods, processes and apparatus generally disclosed in the specifications and claims of U.S. Patent No. 6,020,141 and/or allowed U.S. Patent Application Serial no. 08/853,459.

Licensor was granted a limited, nonexclusive license to the method claims of ThermoFluor screening technology. As part of this settlement agreement, until March 7, 2003, Licensee is precluded from using ThermoFluor screening technology in the Hepatitis C Virus infection area as part of collaborative agreements or as part of our internal drug programs. In addition, Licensee is precluded from using ThermoFluor screening technology as part of more than one collaboration agreement in the area of infection.

Field of Use
Licensee Internal Program(s) shall mean drug discovery and/or development program(s) in any therapeutic field conducted for and by Licensee on-site at a Licensee facility.

During the Restriction Period, Licensor may refer to Licensee any third parties that have requested that Licensor screen multiple targets to identify leads or drugs that are effective in any field other than Infection.

Licensee shall be free to use ThermoFluor Screening Technology without restriction in any Licensee Internal Program, except in the Hepatitis C Virus Field during the Restriction Period, and to license or transfer, in any manner, any compounds discovered or optimized through such use of ThermoFluor Screening Technology. Licensee shall not use ThermoFluor Screening Technology in the Hepatitis C Virus Field during the Restriction Period.

ThermoFluor screening process and our ability to rapidly select and synthesize compounds from our libraries compress an important segment of the R&D process, from assay set-up to the generation of a series of lead compounds with potential in vivo efficacy, from fourteen to thirty months at many pharmaceutical companies to as little as seven to ten months. This is expected to reduce resources required and development costs per target, allow more targets to be discovered with a given set of resources and accelerate time to market of successful drugs

Licensee is a post-genomics drug discovery company that has developed a unique integration of proprietary technologies to provide an accelerated and improved methodology for gene-to-clinic small molecule drug discovery.

IPSCIO Record ID: 253904

License Grant
Licensor grants to English Licensee an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property that is jointly owned by the Parties, as embodied in or related to any Designated Compound(s), collectively, the Licensed Technology, to research, develop, make, have made and use such Designated Compound to develop Licensed Products, and, to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.
License Property
The parties pursue a collaborative screening process to identify compounds exhibiting a high degree of chemical binding activity to targets designated by Licensee from among the Licensor libraries of mass-encoded small molecule compounds and which have activity in bioassays or functional assays.

The know-how and patents include screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Licensed Product(s) means any product which includes a Designated Compound or any derivatives, improvements and components thereof; and the development, manufacture, use, or sale.

Licensor Library includes ALIS, the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to the Licensor that is used to identify multiple classes of chemical ligands against target protein.

Field of Use
The Field means the diagnosis or treatment of any disease in humans.  The Licensee is identifying potential pharmaceutical products for treatment of certain human diseases and is identifying compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 315803

License Grant
Licensee hereby grants to Licensor a non-exclusive, royalty bearing license, under Licensee Program Know-How Patent Rights, Licensee Contributed Know-How Patent Rights, Licensee Program Methodology Patent Rights, Licensee Program Know-How, Licensee Contributed Know-How and Licensee Program Methodology, to use Licensor Accessible Program Clones and Proteins encoded therein in order to discover, research, develop, make, import, use, offer to sell and sell Licensor Small Molecule Drugs in the Territory; such license shall include the right to grant sublicenses.
License Property
Program Clone means a clone (including the DNA sequence information, whether partial or full-length, pertaining to the clone), identified in the course of the Licensee Discovery Program or included in the Existing Tango Technology, Licensee Contributed Know-How or Licensor Contributed Know-How. Licensee Program Methodology Patent Right' means a Patent Right that relates to methods that are or were at any time included in Licensee Program Metholodogy.

Protein means a high molecular weight (i.e., weighing greater than 1000 daltons) polymer compound composed of a variety of amino acids joined by peptide linkages, including allelic variants thereof and post-translationally modified variants thereof (i.e., glycosylated Proteins). For purposes of this Agreement, Protein does not include an Antibody.

Small Molecule Drug means a therapeutic or prophylactic product, the active ingredient of which is a synthetic small molecule (including but not limited to a Peptido Mimetic), a natural product or a macromolecule that
(a) is identified in a screening assay on the basis of its interaction with a biological target that has been identified through use of a Program Clone, or (b) is designed or developed using medicinal chemistry, SAR or combinatorial
chemistry techniques to interact with a biological target that has been identified through use of a Program Clone, provided, however, that a Small Molecule Drug does not include any Therapeutic Product or any therapeutic and/or prophylactic product in which the active ingredient is a Protein, an Antibody, an Antisense Drug or a Gene Therapy Drug.

Gene Therapy Drug means any drug or drug candidate, excluding an Antisense Drug, which consists of nucleic acid or a functional analog, derivative or homologue thereof and which, upon delivery by any means, provides a gene product encoded therein which is expressed.

Antisense Drug means any drug or drug candidate which consists of nucleic acid or a functional analog, derivative or homologue thereof and which is complementary to a segment of DNA of a target gene or such target genes cognate RNA and which, upon delivery by any means, alters the transcription, processing, elaboration, RNA expression or Protein production of or by such target gene.

Antibody means (a) a molecule comprising four (4) polypeptide chains (two (2) identical light chains and two (2) identical heavy chains) that are held together by disulfide bonds and form two (2) identical antigen binding sites or (b) any combination, fragment or altered form of a molecule(s) of the type described in (a) (e.g., single chain antibodies).

Licensor Small Molecule Drug means a Small Molecule Drug identified or designed by Licensor through the use of a Licensor Accessible Program Clone and/or the Protein encoded therein.

Existing Tango Technology means the cDNA libraries, genomic sub-libraries, signal peptide trap libraries (including the clones derived from such libraries and the Proteins encoded therein) and the Proteins and all associated data and information.

Therapeutic Product means a therapeutic and/or prophylactic product in which the active ingredient is a Program Protein or a Derivative thereof.

Peptido Mimetic means  synthetic organic molecule that (a) is designed or developed using medicinal, SAR or combinatorial chemistry techniques to incorporate key structural features of a Protein (the Mimicked Protein). Cb) if a peptide • has an amino acid sequence that is at least fifty percent (50%) different from that of the  Mimicked Protein, and (c) has a molecular weight that is less than twenty (20%) percent of that of the Mimicked Proteina,

Diagnostic Product means any diagnostic product, in the form of a device, compound, kit or service, with utility in the diagnosis, prognosis, prediction or disease management of a disorder that (a) is developed through the use of Licensee Program Know-How or, subject to any limitations on the use of such Know-How by Licensor, Licensee Contributed Know-How and/or is covered by a Valid Claim included in Licensee Program Know-How Patent Rights or, subject to any limitations on the use of such Patent Rights by Licensor, Licensee Contributed Know-How Patent Rights, (b) embodies, or operates through the detection of a Program Clone or a Program Protein (or a Derivative thereof), and (c) will complement the use of any therapeutic product under development or marketed by Licensor or a development or marketing partner of Licensor (a Licensor Corresponding Drug).

Licensee Program Methodology means any methods (including without limitation bioinformatics tools, processes, protocols, assays, automated and semi-automated techniques, molecular biology methods and other methods for the discovery, production and/or characterization of Proteins), that (a) are developed in the course of the Licensee Discovery Program, including any improvements in methods technology derived from, or based upon, any Licensor Contributed Know-How and/or Licensee Contributed Know-How and (b) are not properly in the public domain.

Licensee Discovery Program means the therapeutic Protein  discovery program to be undertaken by Licensee pursuant to this Agreement, with the goal of identifying and qualifying potential therapeutic Proteins for further pre-clinical development, clinical development, manufacturing and commercialization, as described in greater detail in the Program Plan.

Licensee Accessible Program Clone means (a) a Program Clone  that is not identified through the use of Licensor Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensor Contributed Know-How and with respect to which either (i) Licensor has not placed any limitation on Licensees use of such Program Clone for the identification or design of Licensee Small  Molecule Drugs or (ii) Licensor has placed the limitation that Licensee shall not have the right to use such Program Clone for the identification or design of Licensee Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Licensor Accessible Program Clone means (a) a Program Clone that is not identified through the use of Licensee Contributed Know-How, or (b) a Program Clone that is identified through the use of Licensee Contributed Know-How and with respect to which either (i) Licensee has not placed any limitation on Licensors use of such Program Clone for the identification or design of Licensor Small Molecule Drugs or (ii) Licensee has placed the limitation that Licensor shall not have the right to use such Program Clone for the identification or design of Licensor Small Molecule Drugs for a period of twelve (12) months from the date on which such Program Clone is identified and such twelve (12) month period has elapsed.

Field of Use
The field of use is for the therapeutic and/or prophylactic application in human health care of Proteins or Derivatives thereof. The goal is to identify and qualify potential therapeutic proteins, small molecule targets and diagnostics for further development and commercialization.

IPSCIO Record ID: 294288

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products for the Target in the Field in the Territory.
License Property
Licensees target is P53 Tumor protein p53 (Li•Fraumeni syndrome}

Licensor has intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (RNAi).

Patents include short double-stranded RNAs as therapeutics.

Field of Use
Field means the use of therapeutic RNAi Products against p53 for the treatment of hypoxic injury in humans, including but not limited to renal failure.

Hypoxic injury implies damage to cells resulting only from decreased oxygen tension. This is a relatively unusual pattern of injury in its pure form. Hypoxia can result from decreased atmospheric oxygen concentration, abnormal lung function, and decreased oxygen-carrying capacity in the blood (e.g., severe anemia).

IPSCIO Record ID: 237263

License Grant
Licensor grants a non-exclusive, non-transferable license, without the right to sublicense, to Licensed Patents and Licensed Know-How to use the Instrument solely for the internal research and development activities.

Licensor grants a world-wide, non-exclusive, nontransferable license, without the right to sublicense, to make, use, sell, off er for sale and import Licensed Products for genotyping HAPâ„¢ Markers in all fields other than human and animal infectious diseases. Excluded from this grant is the right to make, sell, offer for sale or import the Licensors ProbeTecâ„¢ ET.

License Property
Licensed Know-How shall mean Licensors know-how related to Licensed Patents, the ProbeTecâ„¢ ET, and custom software for the ProbeTecâ„¢ ET. Licensed KnowHow shall also include, upon written request from Licensee, Licensors know-how necessary in the design and development of assays that utilize ProbeTecâ„¢ ET.

The patents include, but are not limited to, Nucleic Acid Target Generation,  Oligonucleotides for amplification and detection of hemochromatosis, and, Methods for detecting nucleic acid sequence variations.

Licensed Products shall mean any device, instrument, service, kit, composition of matter, material, product or component thereof that utilizes Licensed Know-How.

Instrument shall mean the Licensors ProbeTecâ„¢ ET installed in Licensees HAPâ„¢ Typing facility in New Haven, CT.

HAPâ„¢ Marker shall mean a polymorphism or any ordered combination of two or more polymorphisms present at a locus on a single chromosome that is contained in the Licensee HAPâ„¢ Database during the term of this Agreement or that is discovered from any gene where such discovery was made solely by employees of Licensee or others acting on behalf of Licensee, or, jointly by employees of Licensees or others acting on its behalf and employees of a HAPâ„¢ Partner or others acting on its behalf or for which a HAPâ„¢ Partner requests Licensee to develop genotyping assays or provide genotype data.

Licensor ProbeTecâ„¢ ET shall mean the clinical platform for infectious disease testing owned by Licensor using Strand Displacement Amplification Technology or SDA Technology and real time detection means.

LICENSED PATENTS

1. US Patent No. 5,270,184, entitled 'Nucleic Acid Target Generation'

2. US Patent No. 5,422,252, entitled 'Simultaneous Amplification of Multiple Targets'

3. US Patent No. 5,455,166, entitled 'Strand Displacement Amplification'

4. US Patent No. 5,536,649, entitled 'Decontamination of Nucleic Acid Amplification Reactions'

5. US Patent No. 5,547,861, entitled 'Detection of nucleic acid amplification'

6. US Patent No. 5,648,211, entitled 'Strand Displacement Amplifcation Using Thermophilic Enzymes'

7. US Patent No. 5,624,825, entitled 'Simultaneous Amplification of Multiple Targets'

8. US Patent No. 5,691,145, entitled 'Detection of nucleic acids using G-quartets'

9. US Patent No. 5,712,124, entitled 'Strand Displacement Amplification'

10. US Patent No. 5,736,365 entitled 'Multiplex nucleic acid amplification'

11. US Patent No. 5,744,311 entitled 'Strand displacement amplification using thermophilic enzymes'

12. US Patent No. 5,840,487, entitled 'Internal controls for isothermal nucleic acid amplification reactions'

13. US Patent No. 5,863,736, entitled 'Method, apparatus and computer program products for determining quantities of nucleic acid sequences in samples'

14. US Patent No. 5,888,739, entitled 'Detection of nucleic acids using G-quartets and Itetraplexes'

15. US Patent No. 5,916,779, entitled 'Strand displacement amplification of RNA
targets'

16. US Patent No. 5,919,630, entitled 'Detection of nucleic acids by fluorescence quenching'

17. US Patent No. 5,928,869, entitled 'Detection of nucleic acids by fluorescence quenching'

18. US Patent No. 5,935,791, entitled 'Detection of nucleic acids by fluorescence quenching'

Field of Use
Licensee creates personalized medicines through the integration of pharmacogenomics into drug development and marketing.  The fields of human and animal infectious diseases are excluded from this license.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 203296

License Grant
For the Non-Exclusive Research License to Licensors Base Technology,  Licensor grants a non-exclusive, world-wide license under the Base Technology and Collaboration Technology to conduct research and Development activities with respect to Targets, Hits, Research Compounds, Lead Compounds and IND Candidates pursuant to the Research Plan.   Licensor also grants the right to sublicense or transfer the rights granted to Licensee under the Collaboration Technology to  Affiliates; and to Third Parties.
License Property
The Licensed Product shall mean any Product which incorporates a Collaboration Compound as an active ingredient.  The Collaboration Compound shall mean, on a Target-specific basis, a chemical compound that is synthesized or identified by the Parties, and any metabolites, prodrugs, solvates, including without limitation hydrates, analogs, esters, salts, derivatives, stereoisomers, racemates, tautomers and polymorphs of such chemical compound which are determined to be Active. Collaboration Compound shall include any of a Hit, a Research Compound, a Lead Compound or an IND Candidate.

Licensor is a biopharmaceutical company which is focused on the discovery, development and commercialization of small molecules which target post-transcriptional control of protein expression, and which owns certain proprietary technologies for developing small molecule drugs by targeting such post transcriptional control mechanisms, including GEMS.

GEMS (Gene Expression Modulation by Small-Molecules) is a novel drug discovery platform technology which enables identification of compounds that target the post-transcriptional regulation of gene expression.

Gene Expression Modulation by Small-molecules (GEMS) is PTC’s novel and proprietary screening technology for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology modulate gene expression by targeting the post-transcriptional control processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules.

Field of Use
The Field shall mean the prevention, treatment or diagnosis of all diseases or conditions in humans or animals.

Parties wish to collaborate on specific therapeutic targets with a focus on cardiovascular, metabolic and addictive diseases, and the discovery of clinical candidate small molecules which act upon such targets.
This agreement pertains to drug discovery.

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 289199

License Grant
This amendment is made to provide for royalties.

Licensor grants to Licensee, an affiliate company, an exclusive license under the Exclusively Licensed Patent Rights and the Improvement Patent Rights owned or controlled by Licensor to make, have made, import, use, sell, and offer for sale Licensed Products in the Field throughout the world, and, a nonexclusive license under the Technology to make, have made, import, use, sell, offer for sale, reproduce, distribute, display, perform, create derivative works of, and otherwise exploit Licensed Products in the Field throughout the world.

License Property
Licensor Technology means the Exclusively Licensed Patent Rights, Improvement Patent Rights and the Technology.

Licensed Product means any product, device, system, article of manufacture, composition of matter, or process or service that is covered by, or is made by a process covered by, any Valid Claim or that utilizes Technology in material part.

The patents are

Methods and composition for therapeutic use of RNA interference;  Carbohydrate-modified polymers, compositions and uses related thereto; Nuclear localization sequences and uses related thereto; Cyclodextrin-based polymers for therapeutic delivery;  Compositions and uses of motor protein-binding moieties; Compositions and used of Dynein-binding moieties; Linear Cyclodextrin polymers; and, Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network.

Cyclosertâ„¢ is a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Cyclodextins (a cyclic sugar molecule) have been used with great success for drug delivery, principally acting to solubilize drugs that otherwise would not dissolve. In polymeric form, cyclodextrins have been shown to be non-toxic and non-immunogenic, and by enabling the manipulation of particle size and other characteristics, to improve drug properties and performance. The Cyclosert delivery platform has been designed to be used with a variety of drug molecules and targeting agents.

Field of Use
Licensor has licensed its Cyclosertâ„¢ delivery technology to an affiliate company for the development and commercialization of RNAi therapeutics. Under

The Field means the discovery, development, and commercialization of RNAi Therapeutics. The term RNAi Therapeutic refers to small interfering RNAs (siRNAs), hairpin RN As or other nucleic acids or analogs thereof that are substrates of the enzyme Dicer and/or associates with intracellular proteins to form an assembly known as a RNA-induced silencing complex (RISC), and which causes sequence dependent gene silencing.

IPSCIO Record ID: 322362

License Grant
Licensor grants an exclusive, worldwide license to develop, manufacture and commercialize PCSK9.
License Property
PCSK9 is a RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease.

Field of Use
PCSK9 is for the treatment of hypercholesterolemia and other human diseases, including inclisiran.

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins.

Inclisiran is an experimental drug for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.

IPSCIO Record ID: 309678

License Grant
The Licensor hereby grants to the Japanese Licensee an exclusive (even as to Licensor (Licensor Retained Rights)) license under the Licensor Technology and Licensor’s interest in the Collaboration Technology (with the right to grant sublicenses (Licensee Sublicensing Rights)), solely to conduct any Project during the Research Term (the “Research License”). Licensor will disclose all Licensor Technology to Licensee immediately upon execution of this Agreement or from time to time upon request of Licensee.
License Property
Licensor Technology means Licensor Know-How and Licensor Patent Rights. Collaboration Technology means Collaboration Know-How and Collaboration Patent Rights.

Licensor has expertise and proprietary technical information and know-how relating to application of protein folding, trafficking and clearance-based, small molecule therapeutics for the treatment of diseases and is committed to the research and development of therapeutic methods and products for the treatment of diseases.

Licensed Product means any product for use in the Field that contains a Development Compound (or any pharmaceutically acceptable radioisomers, stereoisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, prodrugs, and ester forms thereof) as an Active Ingredient.

Development Compound means an Active Compound in a Hit Series or derived from a Hit Series that is designated by Licensee, in Licensee’s sole discretion, for further Development by Licensee’s exercise of its Development Option for that Active Compound in accordance with this agreement (Development Compounds). For avoidance of doubt, Development Compound includes Co-Developed Compounds.

Active Compound means a Compound that is shown in functional, in vitro testing using living human cells, and appropriately counter-screened or otherwise verified, to satisfy the threshold criteria set forth in the Research Plan for an effect as a UPR Modulator in the Indication specified by the Research Plan for the relevant Project.

The Licensor’s DRT™ platform utilizes functionally pertinent assays and disease relevant models to identify highly translatable therapies associated with the modulation of protein homeostasis pathways within the cell.

Field of Use
Licensee is intended to reduce the accumulation of unfolded proteins in the endoplasmic reticulum, which is observed in many diseases caused by an imbalance in the proteostasis network, including genetic, neurodegenerative and retinal degenerative diseases.

The proteostasis network (PN) comprises the intricately regulated interplay of signaling processes and molecular machines involved in the synthesis, folding, and clearance of the diverse spectrum of proteins comprising the folded, native proteome.

The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.

A novel approach to drug discovery will enable rapid discovery and development of therapies for important unmet medical needs.  The collaboration will focus on one genetic disease, and further explore additional indications that can be affected through modulation of the UPR pathway. Stress induced by accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many diseases which are now recognized as protein conformational diseases, including genetic diseases, neurodegenerative diseases, and retinal degenerative diseases. Selective modulation of the UPR pathway in non-clinical investigations improved the stress response and restored function, suggesting that it can be beneficial as potential novel disease-modifying therapies for multiple diseases with high unmet medical needs.

Licensee is engaged in the research, development, production, marketing and sale of therapeutics and is interested in the development and commercialization of pharmaceutical products for treatment  through regulation of the proteostasis network with a focus on modulations of the human unfolded protein response (UPR).

IPSCIO Record ID: 203544

License Grant
Pursuant to this agreement between a Third Party and the Licensee of both the USA and Switzerland, the Third Party grants to Licensee in the Territory in the Field an irrevocable, with regard to Licensors Patents for which the Third Party has rights to sublicense, a non-exclusive sublicense with respect to the Licensors Patents, with the right to sublicense, but solely in connection with a third party collaboration for research, manufacturing, development or commercialization of a pharmaceutical product or otherwise in connection with the research, manufacturing, development or commercialization of a Licensees Licensed
Product, under the Patents to develop, make, import, use, offer for sale or sell Licensed Product.
License Property
Certain patent rights relate to siRNA constructs, including meroduplex technology, and chemical modifications of nucleic acids, including unlocked nucleic acid technology (“UNA”).

“Dicer Substrate Technology represents a second generation of gene silencing that can generate drug candidates with greater potency and longer duration of action than earlier RNAi approaches, because of the distinct way in which it engages this important biological pathway.

The Third Party controls certain patents and patent applications owned by Licensor relating to siRNA constructs, including the dicer substrate.  The Licensor patents address nanoparticles for delivery of nucleic acids and stable double-stranded RNA.

U.S. 60/497,740 – NANOPARTICLES FOR DELIVERY OF NUCLEJC ACIDS AND
STABLE DOUBLE-STRANDED RNA

U.S. 11/219,625 – DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES HAVING RJBOTHYMIDINE

PCT/US2006/020627 – MODIFICATION OF DOUBLE-STRANDED RJBONUCLEIC ACID MOLECULES

U.S. 60/720,072 – CHEMICALLY MODIFIED DOUBLE-STRANDED RJ BONUCLEIC
AICDS AND PEPTlDES

Field of Use
The Field means the use of a Licensed Product for the treatment or prevention of disease in humans other than by delivery of a Licensed Product directly into or onto the surface of the eye, by the delivery of a Licensed Product directly into the ear or aural canal, or to target one or more specific viruses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.